The short version of pentadecapeptide fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-10-06 and is reviewed periodically as new material appears.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength that captures the peptide backbone. The main peak area is reported as a percentage of total peak area, which serves as a conventional purity figure. Mass spectrometry provides an independent check on molecular mass and helps confirm the expected sequence. Additional tests may include amino acid analysis and water content determination. Results are only comparable when the same column, gradient, and detection settings are used.
Peptides are susceptible to hydrolysis, oxidation, and aggregation, and BPC-157 is no exception. The lyophilized powder form is generally more stable than a solution because residual moisture is low and molecular mobility is reduced. Once dissolved, the peptide is exposed to water, oxygen, and trace metal ions that accelerate degradation. Light exposure and repeated freeze-thaw cycles are also commonly cited as sources of loss. These general principles guide most handling recommendations found in supplier documentation.
Standard practice for the solid form is storage at minus twenty degrees Celsius or colder, kept dry and away from light. Containers are usually sealed with a desiccant to limit moisture uptake. Reconstituted solutions are typically held at two to eight degrees Celsius and used within a short window, because potency can decline over days to weeks depending on the buffer and concentration. Freezing an already dissolved sample may help, though repeated thawing is discouraged. Specific shelf-life claims vary between suppliers and are rarely supported by published stability studies.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | Linear, fifteen residues |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Approximate mass | 1419 Da | Value reported for the free peptide |
| Reported origin | Fragment of a gastric juice protein | Used as the design template |
| Common synonyms | Body protection compound 157; PL 14736 | Naming varies across papers and suppliers |
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
Edman degradation, developed by Pehr Edman, is a method of sequencing amino acids in a peptide. In this method, the amino-terminal residue is labeled and cleaved from the peptide without disrupting the peptide bonds between other amino acid residues.
=== Timing of solutions === There is significant debate regarding the urgency of addressing the short-term and long-term budget challenges. Prior to the 2008-2009 U.S. recession, experts argued for steps to be put in place immediately to address an unsustainable trajectory of federal deficits. For example, Fed Chair Ben Bernanke stated in January 2007: "The longer we wait, the more severe, the more draconian, the more difficult the objectives are going to be. I think the right time to start was about 10 years ago." However, experts after the 2008-2009 U.S. recession argued that longer-term austerity measures should not interfere with measures to address the short-term economic challenges of high unemployment and slow growth. Ben Bernanke wrote in September 2011: "...the two goals--achieving fiscal sustainability, which is the result of responsible policies set in place for the longer term, and avoiding creation of fiscal headwinds for the recovery--are not incompatible. Acting now to put in place a credible plan for reducing future deficits over the long term, while being attentive to the implications of fiscal choices for the recovery in the near term, can help serve both objectives." IMF managing director Christine Lagarde wrote in August 2011
Polyadenylation tail: Creates a polyadenylation tail at the end of the transcribed pre-mRNA that protects the mRNA from exonucleases and ensures transcriptional and translational termination: stabilizes mRNA production. Minimal UTR length: UTRs contain specific characteristics that may impede transcription or translation, and thus the shortest UTRs or none at all are encoded for in optimal expression vectors. Kozak sequence: Vectors should encode for a Kozak sequence in the mRNA, which assembles the ribosome for translation of the mRNA.
A molecular dynamics simulation requires the definition of a potential function, or a description of the terms by which the particles in the simulation will interact. In chemistry and biology this is usually referred to as a force field and in materials physics as an interatomic potential. Potentials may be defined at many levels of physical accuracy; those most commonly used in chemistry are based on molecular mechanics and embody a classical mechanics treatment of particle-particle interactions that can reproduce structural and conformational changes but usually cannot reproduce chemical reactions. The reduction from a fully quantum description to a classical potential entails two main approximations. The first one is the Born–Oppenheimer approximation, which states that the dynamics of electrons are so fast that they can be considered to react instantaneously to the motion of their nuclei. As a consequence, they may be treated separately. The second one treats the nuclei, which are much heavier than electrons, as point particles that follow classical Newtonian dynamics. In classical molecular dynamics, the effect of the electrons is approximated as one potential energy surface, usually representing the ground state. When finer levels of detail are needed, potentials based on quantum mechanics are used; some methods attempt to create hybrid classical/quantum potentials where the bulk of the system is treated classically but a small region is treated as a quantum system, usually undergoing a chemical transformation.
=== Class III === Class III fusion proteins are distinct from I and II. They typically consist of five structural domains, where domains 1, 2 and 4 often contain more β-sheets and domains 3 and 5 are richer in α-helices (defining domain 1 as being closer to the N-terminus and 5 closer to the C-terminus). In the pre-fusion state, the domains nest, with domain 1 protected by domain 2, which is nested in domain 3, which is protected by domain 4. Domain 1 contains a bipartite site, likely for membrane fusion, within the loops connecting its long beta strands, and domain 5 serves as a linker between domain 4 and the C-terminal membrane-proximal and transmembrane domains. Domain 3 refolds upon fusion, while domain 5 loses its alpha helical structure.
Sources: en.wikipedia.org
The skin (integument) is a composite organ, made up of at least two major layers of tissue: the epidermis and the dermis. The epidermis is the outermost layer, providing the initial barrier to the external environment. It is separated from the dermis by the basement membrane (basal lamina and reticular lamina). The epidermis contains melanocytes and gives color to the skin. The deepest layer of the epidermis also contains nerve endings. Beneath this, the dermis comprises two sections, the papillary and reticular layers, and contains connective tissues, blood vessels, glands, follicles, hair roots, sensory nerve endings, and muscular tissue. Between the integument and the deep body musculature there is a transitional subcutaneous zone made up of very loose connective and adipose tissue, the hypodermis. Substantial collagen bundles anchor the dermis to the hypodermis in a way that permits most areas of the skin to move freely over the deeper tissue layers.
=== 1974–1977: Arrival of Neil Peart and foray into progressive rock === After auditioning five drummers, Lifeson and Lee picked Neil Peart, who joined on July 29, 1974, which was two weeks before the group's first US tour. They performed their first concert together on August 14 at the Civic Arena in Pittsburgh, opening for Uriah Heep and Manfred Mann's Earth Band to more than 11,000 people. Peart assumed the role of lyricist; Lifeson and Lee had little interest in the job and recognized Peart's wider vocabulary range from reading regularly. Lifeson and Lee focused primarily on the music, with the new material displaying their influences from progressive rock bands Yes and Pink Floyd. When the U.S. tour concluded in December 1974, Rush had reached its peak of No. 105 on the U.S. Billboard 200 chart. Fly by Night (1975), Rush's first album with Peart, saw the inclusion of the story song "By-Tor & the Snow Dog", replete with complex arrangements and a multi-section format. Lyrical themes also underwent dramatic changes because of Peart's love for fantasy and science-fiction literature. Despite the new styles, some other songs on the album mirrored the simplistic blues style found on Rush's debut. "Fly by Night" was released as a single that reached No. 45 in Canada. The album reached No. 9 in Canada, where it was certified platinum by the Canadian Recording Industry Association (CAN) for selling 100,000 copies and by the Recording Industry Association of America (RIAA) for selling 1 million copies in the U.S. Caress of Steel (1975) followed Fly by Night.
The two substrates of this enzyme are D-xylose and oxidised nicotinamide adenine dinucleotide phosphate (NADP+). Its products are D-xylono-1,5-lactone, reduced NADPH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is D-xylose:NADP+ 1-oxidoreductase. Other names in common use include D-xylose (nicotinamide adenine dinucleotide phosphate), dehydrogenase, D-xylose-NADP+ dehydrogenase, D-xylose:NADP+ oxidoreductase, and D-xylose 1-dehydrogenase (NADP+).
Afterwards, he reinforced this vision by implementing measures such as requiring ministers to declare their assets, limiting land applications to one piece per leader, discouraging conflicts of interest with public-listed companies, and advising against ostentation and visits to nightclubs. Mahathir further emphasized this vision by launching the "Leadership-by-Example" campaign in 1983 at Stadium Tun Razak, Kuala Lumpur, encouraging leaders and civil servants to uphold integrity, professionalism, and ethical behaviour in order to inspire public trust and ensure that national objectives were achieved through exemplary conduct. In 1983, Mahathir undertook one of the first challenges he had with Malaysia's royalty. The position of Yang di-Pertuan Agong, the Malaysian head of state, was due to rotate into either the elderly Idris Shah II of Perak or the controversial Iskandar of Johor, who had only a few years earlier been convicted of manslaughter. Mahathir had grave reservations about the two Sultans, who were both activist rulers of their own states. Mahathir tried to pre-emptively limit the power that the new Agong could wield over his government. He introduced to parliament amendments to the Constitution to deem the Agong to assent to any bill that had not been assented within 15 days of passage by Parliament. The proposal removed the power to declare a state of emergency from the Agong and placed it with the prime minister.
Candelariella immarginata is a species of parasitic, saxicolous (rock-dwelling) lichen in the family Candelariaceae. Found in the United States, it was formally described as a new species in 2007 by Swedish lichenologist Martin Westberg. The type specimen was collected in the desert west of Grantsville, Utah at an elevation of 4,300 ft (1,300 m); here it was found growing on dry exposed quartzite. At the time of publication, it had also been found in another location in Utah, and two locations in Nevada; its general geographic range is the Great Basin in western North America. In 2015, it was recorded from the White Mountains of California. The species is lichenicolous on Aspicilia species and pyrenocarpous lichens. The specific epithet immarginata refers to the lack of a thalline margin on the apothecia. Secondary compounds that have been detected in the lichen (using high-performance liquid chromatography) include calycin, pulvic acid lactone, vulpinic acid, and pulvinic acid.
Sources: en.wikipedia.org
It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.
The sequence corresponds to a segment of a naturally occurring gastric protein, so related sequence material exists in the body. The peptide itself as sold and studied is a laboratory-synthesized product. Whether an identical free peptide circulates naturally is not established.
No major regulatory agency has approved it as a medicine for any indication. It appears in research supply channels and, in some jurisdictions, in compounded preparations. Clinical use therefore sits outside standard approved-product pathways, and regulatory status varies by country.
Reversed-phase HPLC separates the sample into peaks, and the main peak is expressed as a percentage of total peak area. Mass spectrometry is then used to confirm that the molecular mass matches the expected value.